Vericel (VCEL) Capital Expenditures (2010 - 2026)
Vericel (VCEL) posted Capital Expenditures of $1.7 million for Q2 2026, up 18.28% sequentially from $1.5 million in Q1 2026, and down 78.75% YoY from $8.1 million in Q2 2025.
Vericel (VCEL) Capital Expenditures (2010 - 2026) Analysis & Trends
Vericel has reported Capital Expenditures for 16 years, with the latest figure at $1.7 million in Q2 2026.
- Quarterly Capital Expenditures fell 78.75% year-over-year to $1.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.0 million (down 85.59% YoY) and the FY2025 annual result came in at $27.2 million, down 57.54% from the prior year.
- Capital Expenditures improved to $1.7 million in Q2 2026 per VCEL's latest filing, from $1.5 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $19.4 million in Q3 2024 and troughed at $1.4 million in Q4 2022.
- A 5-year average of $6.8 million and a median of $3.2 million in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures soared 514.24% in 2024, then tumbled 89.72% in 2026.
- Over 5 years, Capital Expenditures stood at $1.4 million in 2022, then soared by 479.08% to $7.8 million in 2023, then surged by 75.97% to $13.8 million in 2024, then tumbled by 84.14% to $2.2 million in 2025, then decreased by 20.99% to $1.7 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $1.7 million, $1.5 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.73 Mn |
| Jun 30, 2026 | 1.73 Mn |
| Mar 31, 2026 | 1.26 Mn |
| Mar 31, 2026 | 1.26 Mn |
| Dec 31, 2025 | 26.03 Mn |
| Dec 31, 2025 | 26.03 Mn |
| Sep 30, 2025 | -21.22 Mn |
| Sep 30, 2025 | -21.22 Mn |
| Jun 30, 2025 | 8.13 Mn |
| Jun 30, 2025 | 8.13 Mn |
| Mar 31, 2025 | 14.21 Mn |
| Mar 31, 2025 | 14.21 Mn |
| Dec 31, 2024 | -38.29 Mn |
| Dec 31, 2024 | -38.29 Mn |
| Sep 30, 2024 | 19.41 Mn |
| Sep 30, 2024 | 19.41 Mn |
| Jun 30, 2024 | 18.66 Mn |
| Jun 30, 2024 | 18.66 Mn |
| Mar 31, 2024 | 12.12 Mn |
| Mar 31, 2024 | 12.12 Mn |